Approvement of combination therapy of GT919 from CDE for multiple myeloma

ON：2024-03-12 TAG：GLUETACS THERAPEUTICS

Today, Gluetacs Therapeutics’ molecular glue pipeline GT919, developed on the GlueTacs^® platform, receives approval from CDE to enter the systemic combination therapy stage for multiple myeloma, undergoing preliminary evaluation of safety and efficacy.